Cel-Sci
CVM
$1.63
Share price
10.14%
Change (1 day)
-31.51%
Change (1 year)
Categories
P/S ratio for Cel-Sci (CVM)
P/S ratio as of May 2024 (TTM): N/A
According to Cel-Sci 's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0. At the end of 2023 the company had a P/S ratio of N/A.
P/S ratio history for Cel-Sci from 2001 to 2023
PS ratio at the end of each year
| Year | P/S ratio | Change |
|---|---|---|
| 2023 | N/A | |
| 2022 | N/A | |
| 2021 | N/A | |
| 2020 | N/A | |
| 2019 | N/A | |
| 2018 | N/A | |
| 2017 | N/A | |
| 2016 | N/A | |
| 2015 | N/A | |
| 2014 | N/A | |
| 2013 | N/A | -100% |
| 2012 | 772 | 239.78% |
| 2011 | 227 | -6.82% |
| 2010 | 244 | -92.01% |
| 2009 | > 1000 | -56.16% |
| 2008 | > 1000 | 345.41% |
| 2007 | > 1000 | 267.07% |
| 2006 | 426 | 149.1% |
| 2005 | 171 | 29.2% |
| 2004 | 132 | -35.11% |
| 2003 | 204 | 375.81% |
| 2002 | 42.9 | -46.83% |
| 2001 | 80.6 |
P/S ratio for similar companies or competitors
| Company | P/S ratio | P/S ratio differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | 3.88 | N/A | 🇺🇸 USA |
 Amgen AMGN | 5.30 | N/A | 🇺🇸 USA |
 Xencor XNCR | 8.65 | N/A | 🇺🇸 USA |
 Curis CRIS | 9.71 | N/A | 🇺🇸 USA |
 Teva Pharmaceutical Industries TEVA | 1.01 | N/A | 🇮🇱 Israel |
 BioCryst Pharmaceuticals
BCRX | 2.79 | N/A | 🇺🇸 USA |
 Emergent BioSolutions
EBS | 0.1689 | N/A | 🇺🇸 USA |
 Eterna Therapeutics ERNA | 136 | N/A | 🇺🇸 USA |